Emerging Gene Therapeutics for Epidermolysis Bullosa under Development
International Journal of Molecular Sciences · 13.02.2024 · 25 (4) · 2243
DOI: 10.3390/ijms25042243 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 13.02.2024. Verfasst von Johannes Bischof und 2 weiteren Autor:innen. Beteiligte Einrichtung: EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Par…. Hauptthemen laut MEDLINE: Epidermolysis Bullosa. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 204 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FWF Austrian Science Fund, Austrian Science Fund (FWF).
Abstract (Originalsprache)
The monogenetic disease epidermolysis bullosa (EB) is characterised by the formation of extended blisters and lesions on the patient’s skin upon minimal mechanical stress. Causal for this severe condition are genetic mutations in genes, leading to the functional impairment, reduction, or absence of the encoded protein within the skin’s basement membrane zone connecting the epidermis to the underlying dermis. The major burden of affected families justifies the development of long-lasting and curative therapies operating at the genomic level. The landscape of causal therapies for EB is steadily expanding due to recent breakthroughs in the gene therapy field, providing promising outcomes for patients suffering from this severe disease. Currently, two gene therapeutic approaches show promise for EB. The clinically more advanced gene replacement strategy was successfully applied in severe EB forms, leading to a ground-breaking in vivo gene therapy product named beremagene geperpavec (B-VEC) recently approved from the US Food and Drug Administration (FDA). In addition, the continuous innovations in both designer nucleases and gene editing technologies enable the efficient and potentially safe repair of mutations in EB in a potentially permanent manner, inspiring researchers in the field to define and reach new milestones in the therapy of EB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria.
- Department of Biosciences and Medical Biology, University of Salzburg, 5020 Salzburg, Austria.
ORCID-Profile: Johannes Bischof, Markus Hierl, Ulrich Koller
Förderung
- FWF Austrian Science Fund
- Austrian Science Fund (FWF)
Zitieren
APA
Bischof, J., Hierl, M., & Koller, U. (2024). Emerging Gene Therapeutics for Epidermolysis Bullosa under Development. International Journal of Molecular Sciences, 25(4), 2243. https://doi.org/10.3390/ijms25042243
Vancouver
Bischof J, Hierl M, Koller U. Emerging Gene Therapeutics for Epidermolysis Bullosa under Development. International Journal of Molecular Sciences. 2024;25(4):2243. doi:10.3390/ijms25042243
BibTeX
@article{Bischof2024,
author = {Bischof, Johannes and Hierl, Markus and Koller, Ulrich},
title = {Emerging Gene Therapeutics for Epidermolysis Bullosa under Development},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {4},
pages = {2243},
doi = {10.3390/ijms25042243}
}
EUVIMED